Vivus inc (VVUS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities:
Net loss

-31,503

-36,950

-30,511

23,302

-93,107

-82,647

-

-

-

-

-

Net loss

-

-

-

-

-

-

-174,946

-139,733

-47,026

-75,434

-53,385

Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Depreciation and amortization

14,702

8,875

811

1,080

1,387

1,112

-

-

-

-

-

Depreciation and amortization

-

-

-

-

-

-

973

271

102

138

75

Amortization of debt issuance costs and discounts

-4,070

18,228

20,442

18,666

17,174

15,923

8,369

-

-

-

-

Amortization of discount or premium on available-for-sale securities

502

-559

-768

-944

-2,282

-4,016

-2,635

-3,950

-3,118

-1,655

-

Net realized gain on investments

-

-

-

-

-

-

-

-

-

5

1,085

Other-than-temporary loss on impaired securities

-

-

-

-

-

-

-

-

-

-

654

Share-based compensation expense

2,026

3,285

2,942

2,284

3,590

9,766

32,397

15,938

7,353

6,443

3,927

Gain on extinguishment of debt

-

1,427

-

-

-

-

-

-

-

-5,958

-

Loss on disposal of property and equipment

-

-

-

-342

-

-

-

-

-

-

-

Unrealized foreign currency remeasurement gain

-

-

-

-

-

-

235

-

-

-

-

Loss on disposal and impairment of property and equipment

-

-

-

-

-

-

-896

-

-

-

-

Inventory impairment charge

-

-

-

-

29,522

2,170

7,525

-

-

-

-

Changes in assets and liabilities:
Accounts receivable

-2,857

13,421

2,709

481

-2,598

-619

9,436

2,778

-

-

-

Inventories

12,623

5,849

1,526

2,584

8,487

-11,886

30,195

22,050

-118

3,225

-

Prepaid expenses and other assets

201

370

-1,069

-1,516

-2,639

-7,734

-2,086

17,366

145

-2,658

2,582

Accounts payable

-1,195

-1,151

5,365

-2,353

-3,370

-329

-14,821

22,202

545

-5,687

-7,289

Accrued research and clinical expenses

-

-

-

-

-

-

-

-

-

-

-4,009

Accrued employee compensation and benefits

-

-

-

-

-

-

-

-

-

-

737

Accrued and other liabilities

1,248

5,838

5,859

-1,524

-889

-9,061

13,170

7,385

15

1,197

1,302

Deferred revenue

-1,213

-1,224

-18,874

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-3,027

329

706

26,465

1,150

-

-

-31,395

Net cash used for operating activities

-

-

-

-

-

-38,105

-135,117

-131,031

-35,920

-66,302

-93,050

Net cash used for operating activities from discontinued operations

-

-

-

-

-

-

-208

-885

-980

2,195

-3,033

Net cash provided by (used for) operating activities

-30,474

-23,607

-16,364

38,165

-46,332

-

-135,325

-131,916

-36,900

-64,107

-96,083

Investing activities:
Fixed asset purchases

42

34

21

211

310

262

1,795

1,669

201

105

237

Acquisition of PANCREAZE license

-

135,000

-

-

-

-

-

-

-

-

-

Release of restricted cash

-

-

-

-

-

-

-

-

-

-700

-

Purchases of available-for-sale securities

16,879

41,506

31,097

135,997

213,536

240,983

329,145

226,654

137,409

209,759

220,606

Proceeds from maturity of available-for-sale securities

42,087

58,101

37,470

60,050

281,250

260,500

242,500

133,250

129,000

243,900

153,185

Proceeds from sales of available-for-sale securities

56,403

62,289

17,660

-

-

-

-

-

-

-

-

Proceeds from sales of available-for-sale securities

-

-

-

36,080

-

-

-

40,763

-

28,487

24,387

Non-current assets

-

-

-

-

-

3,362

1,681

287

-

-

-

Net cash (used for) provided by investing activities

-

-

-

-

-

15,893

-90,121

-54,597

-8,610

63,223

-43,271

Net cash provided by investing activities from discontinued operations

-

-

-

-

-

-

-

-

-

21,546

-171

Net cash used for investing activities

81,569

-56,150

24,012

-40,078

67,404

-

-

-

-8,610

84,769

-43,442

Financing activities:
Net proceeds from debt issuance

-

107,991

-

-

-

-

-

-

-

-

-

Net proceeds from debt issuance

-

-

-

-

-

-

290,247

-

-

-

-

Proceeds from notes payable

-

-

-

-

-

-

-

-

-

-

10,000

Repayments of notes payable

48,649

64,334

26,077

8,738

8,998

-

-

-

-

23,000

1,022

Principal payments of financing leases

203

-

-

-

-

-

-

-

-

-

-

Payments for capped call transactions

-

-

-

-

-

-

34,709

-

-

-

-

Net proceeds from exercise of common stock options

-

78

-

-

-

1,719

13,706

13,250

2,354

3,617

2,350

Sale of common stock through employee stock purchase plan

31

41

38

39

147

405

859

314

-

-

-

Proceeds from sale of common stock through employee stock purchase plan

-

-

-

-

-

-

-

-

211

304

361

Sale of common stock through employee stock purchase plan

-

-

-

-

-

-

-

192,000

45,283

-

102,659

Net cash used for financing activities

-

-

-

-

-

2,124

270,103

205,564

47,848

-19,079

114,348

Net cash used for financing activities from discontinued operations

-

-

-

-

-

-

-

-

-

-4,900

-145

Net cash used for financing activities

-48,821

43,776

-26,039

-8,699

-8,851

-

-

-

47,848

-23,979

114,203

Effect of exchange rates on cash and cash equivalents

-36

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

2,238

-35,981

-18,391

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-10,612

12,221

-20,088

44,657

19,051

2,338

-3,317

-25,322

Supplemental cash flow disclosure:
Interest paid

18,315

18,445

15,350

15,368

18,756

-

-

-

-

-

-

Interest paid

-

-

-

-

-

20,251

5,000

-

-

6,030

2,861

Income taxes paid

46

60

47

59

58

94

32

7

24

41

16

Non-cash investing activities:
Unrealized gain on securities

271

338

8

-

-

-

-

-

-

-

-

Unrealized gain (loss) on securities

-

-

-

-355

-233

-94

33

8

-

-

-

Unrealized gain on securities

-

-

-

-

-

-

-

-

21

7

-357